|Bid||0.4620 x 900|
|Ask||0.5100 x 1300|
|Day's Range||0.4865 - 0.5184|
|52 Week Range||0.3300 - 2.8300|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.93|
Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that its commercial partner, Pint Pharma GmbH, will assist in expanding access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment of MDS, to several selected sites across South America. Pint Pharma is a European-based pharmaceutical company focused on the development, registration and commercialization of specialty-based treatments for the Latin American market and has successfully participated in clinical trials for hematological cancers.
NEWTOWN, Pa., Aug. 14, 2018-- Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Onconova Therapeutics Inc. (NASDAQ: ONTX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 9:00 AM Eastern ...
Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will release its second quarter 2018 financial results on August 14, 2018 before the market opens. The Company will host a conference call on August 14, 2018 at 9:00 a.m. Eastern Time to discuss these results.
On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Onconova Therapeutics Inc. (NASDAQ: ONTX), Ophthotech Corp. (NASDAQ: OPHT), OPKO Health Inc. (NASDAQ: OPK), and OvaScience Inc. (NASDAQ: OVAS).
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4th at 9:00a PDT / 12:00p EDT at the Luxe Sunset Bel Air Hotel in Los Angeles. Mr. Mark Guerin, Chief Financial Officer of Onconova, will be giving the presentation and meeting with investors. "The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro.
In this analysis, my focus will be on developing a perspective on Onconova Therapeutics Inc’s (NASDAQ:ONTX) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...
Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
Onconova Therapeutics Inc’s (NASDAQ:ONTX): Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. The US$28.47M market-cap company announced a latestRead More...
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at Onconova Therapeutics Inc’s (NASDAQ:ONTX) trackRead More...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Onconova Therapeutics Inc. (NASDAQ: ONTX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 9:00 AM Eastern ...